With a course of expectant observation, many patients experience a complete involution without significant sequelae. However, in a fraction of patients, early referral for treatment is important. These patients include:
» » children who have IH in functionally sensitive areas (e.g., eyes, liver, or airways); » » children whose IH causes pain, ulceration, and bleeding; and » » children whose IH causes significant disfigurement (e.g., large lesions on the face).
Management of IH is highly individualized and may include pharmacotherapy or surgery.
Propranolol (Hemangeol™) is an oral medication that was approved by the U.S. Food and Drug Administration as treatment for IH. Steroids used to treat IH mainly include oral steroids and intralesional steroids (e.g., triamcinolone). Surgical interventions such as resection, laser ablation, and radiofrequency ablation may be used as primary management of high-risk lesions prone to complications. The most common type of lasers used to treat IH are pulse dye lasers.
Uncertainty exists about which interventions might be most beneficial as first-line therapies for IH and about when alternative therapies are appropriate after first-line treatment is unsuccessful.
Management of Infantile Hemangioma

K E Y I S S U E
Access to early treatment may be critical for a subset of children facing significant impact from infantile hemangioma (IH). This is a summary of a systematic review 1 evaluating the evidence regarding the efficacy, comparative effectiveness, and adverse effects of pharmacological and surgical therapies for IH. » ü Harms associated with pulse dye lasers included hypopigmentation, bleeding, pain, and scarring.
* These considerations were not evaluated in the systematic review but are offered to assist policymakers in applying this evidence.
Archived: This report is greater than 3 years old. Findings may be used for research purposes, but should not be considered current. HIGH-High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
R E F E R E N C E S
MODERATE-Moderate confidence that the evidence reflects the true effect.
Further research may change our confidence in the estimate of effect and may change the estimate.
LOW-Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of effect and is likely to change the estimate.
INSUFFICIENT-Evidence either is unavailable or does not permit a conclusion. 
STRENGTH OF EVIDENCE SCALE
R E S O U R C E S F O R C L I N I C I A N S A N D C O N S U M E R S
The clinician research summary, Management of Infantile Hemangioma, and the consumer research summary, Treating Infantile Hemangiomas in Children: A Review of the Research for Parents and Caregivers, are free companions to this policymaker research summary. They are meant to assist clinicians and children's parents or caregivers in informed decisionmaking.
O R D E R I N G I N F O R M AT I O N
For electronic copies of this policymaker research summary, the clinician research summary, the consumer research summary, and the full systematic review, visit www.effectivehealthcare.ahrq.gov/infantile-hemangioma. Archived: This report is greater than 3 years old. Findings may be used for research purposes, but should not be considered current.
